{"id":43102,"date":"2019-12-06T14:25:45","date_gmt":"2019-12-06T12:25:45","guid":{"rendered":"https:\/\/newserver.fyb.de\/series-b-imcheck-therapeutics-receives-usd-53-million\/"},"modified":"2019-12-06T14:25:45","modified_gmt":"2019-12-06T12:25:45","slug":"series-b-imcheck-therapeutics-receives-usd-53-million","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/","title":{"rendered":"Series B: ImCheck Therapeutics receives USD 53 million"},"content":{"rendered":"<p>Antwerp (BE) \/ Marseille (FR) \u2014 In a Series B finan\u00adcing round tota\u00adling $53 million, <strong>Gimv<\/strong> has increased its stake in<strong> ImCheck Thera\u00adpeu\u00adtics<\/strong>, an emer\u00adging provi\u00adder of onco\u00adlogy and auto\u00adim\u00admune therapy solu\u00adti\u00adons based in France. The round is led by <strong>Pfizer Ventures<\/strong> (NYSE: PFE) and <strong>Bpifrance<\/strong> and will be joined by new inves\u00adtors. In addi\u00adtion to Gimv, exis\u00adting inves\u00adtors <strong>Life Scien\u00adces Part\u00adners<\/strong> (LSP), <strong>Idin\u00advest Part\u00adners, Kurma Part\u00adners <\/strong>and<strong> Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund<\/strong> also parti\u00adci\u00adpa\u00adted to a signi\u00adfi\u00adcant extent in the increase.<\/p>\n<p>The Series B round funds will be used to finance initial clini\u00adcal trials of ImCheck Thera\u00adpeu\u00adtics\u2019 first-in-class mono\u00adclonal anti\u00adbody ICT01. For exam\u00adple, the broad pipe\u00adline of immu\u00adno\u00admo\u00addu\u00adla\u00adtors for the so-called buty\u00adro\u00adphi\u00adlin super\u00adfa\u00admily will be further expan\u00added and new anti\u00adbody thera\u00adpies in the field of immuno-onco\u00adlogy will be made available to clinics.<\/p>\n<p>Bram Vanpa\u00adrys, Part\u00adner at Gimv and respon\u00adsi\u00adble for the invest\u00adment on the Health &amp; Care plat\u00adform, says: \u201cImCheck has made signi\u00adfi\u00adcant progress since our invest\u00adment in the Series A round. As a result, we are plea\u00adsed to have attrac\u00adted a number of new nota\u00adble inves\u00adtors from the U.S. and Europe for the Series B round. Gimv\u2019s signi\u00adfi\u00adcant invest\u00adment in this finan\u00adcing round demons\u00adtra\u00adtes the poten\u00adtial in ImCheck\u2019s pipe\u00adline of solu\u00adti\u00adons for the onco\u00adlogy and auto\u00adim\u00admune therapy space.\u201d<\/p>\n<p><strong>About GIMV<\/strong><br>\nGimv is a Euro\u00adpean invest\u00adment company with almost 40 years of expe\u00adri\u00adence in private equity. The company is listed on Euron\u00adext Brussels, curr\u00adently mana\u00adges around EUR 1.2 billion and curr\u00adently invests in 50 port\u00adfo\u00adlio compa\u00adnies, which toge\u00adther realize a turno\u00adver of more than EUR 2.5 billion and employ 14,000 people.<\/p>\n<p>Gimv iden\u00adti\u00adfies inno\u00adva\u00adtive, leading compa\u00adnies with high growth poten\u00adtial and supports them on their way to market leader\u00adship. Each of the four invest\u00adment plat\u00adforms Connec\u00adted Consu\u00admer, Health &amp; Care, Smart Indus\u00adtries and Sustainable Cities is mana\u00adged by a dedi\u00adca\u00adted and compe\u00adtent team, each based in Gimv\u2019s home markets \u2014 Bene\u00adlux, France and DACH \u2014 and supported by an exten\u00adsive inter\u00adna\u00adtio\u00adnal network of experts. www.gimv.com<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Antwerp (BE) \/ Marseille (FR) \u2014 In a Series B finan\u00adcing round tota\u00adling $53 million, Gimv has increased its stake in ImCheck Thera\u00adpeu\u00adtics, an emer\u00adging provi\u00adder of onco\u00adlogy and auto\u00adim\u00admune therapy solu\u00adti\u00adons based in France. The round is led by Pfizer Ventures (NYSE: PFE) and Bpifrance and will be joined by new inves\u00adtors. In addition&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":42706,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366],"tags":[],"class_list":["post-43102","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","news-category-private-equity-news-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Series B: ImCheck Therapeutics receives USD 53 million - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Series B: ImCheck Therapeutics receives USD 53 million - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Antwerp (BE) \/ Marseille (FR) \u2014 In a Series B finan\u00adcing round tota\u00adling $53 million, Gimv has increased its stake in ImCheck Thera\u00adpeu\u00adtics, an emer\u00adging provi\u00adder of onco\u00adlogy and auto\u00adim\u00admune therapy solu\u00adti\u00adons based in France. The round is led by Pfizer Ventures (NYSE: PFE) and Bpifrance and will be joined by new inves\u00adtors. In addi\u00adtion [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2019-12-06T12:25:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/03\/a-gimv-e1553254598752.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"701\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Series B: ImCheck Therapeutics receives USD 53 million\",\"datePublished\":\"2019-12-06T12:25:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/\"},\"wordCount\":331,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/03\/a-gimv-e1553254598752.jpg\",\"articleSection\":[\"General\",\"Featured\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/\",\"url\":\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/\",\"name\":\"Series B: ImCheck Therapeutics receives USD 53 million - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/03\/a-gimv-e1553254598752.jpg\",\"datePublished\":\"2019-12-06T12:25:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/03\/a-gimv-e1553254598752.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/03\/a-gimv-e1553254598752.jpg\",\"width\":1000,\"height\":701},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Series B: ImCheck Therapeutics receives USD 53 million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Series B: ImCheck Therapeutics receives USD 53 million - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/","og_locale":"en_US","og_type":"article","og_title":"Series B: ImCheck Therapeutics receives USD 53 million - FYB Financial Yearbook","og_description":"Antwerp (BE) \/ Marseille (FR) \u2014 In a Series B finan\u00adcing round tota\u00adling $53 million, Gimv has increased its stake in ImCheck Thera\u00adpeu\u00adtics, an emer\u00adging provi\u00adder of onco\u00adlogy and auto\u00adim\u00admune therapy solu\u00adti\u00adons based in France. The round is led by Pfizer Ventures (NYSE: PFE) and Bpifrance and will be joined by new inves\u00adtors. In addi\u00adtion [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2019-12-06T12:25:45+00:00","og_image":[{"width":1000,"height":701,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/03\/a-gimv-e1553254598752.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Series B: ImCheck Therapeutics receives USD 53 million","datePublished":"2019-12-06T12:25:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/"},"wordCount":331,"commentCount":0,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/03\/a-gimv-e1553254598752.jpg","articleSection":["General","Featured","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/","url":"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/","name":"Series B: ImCheck Therapeutics receives USD 53 million - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/03\/a-gimv-e1553254598752.jpg","datePublished":"2019-12-06T12:25:45+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/03\/a-gimv-e1553254598752.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2019\/03\/a-gimv-e1553254598752.jpg","width":1000,"height":701},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/series-b-imcheck-therapeutics-receives-usd-53-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Series B: ImCheck Therapeutics receives USD 53 million"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=43102"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/43102\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/42706"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=43102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=43102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=43102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}